LAUSR

1. NCCN. Multiple Myeloma (Version 3.2017); 2016. https://www.nccn. org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed February 15, 2017. 2. Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24(1):29-38. 3. Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. Clin Ther. 2017;39(10):1986-2005.e1985. 4. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (Sirius): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027): 1551-1560. 5. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (Mm-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066. 6. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness— the curious resilience of the $50,000-per-Qaly threshold. N Engl J Med. 2014;371(9):796-797.